180 related articles for article (PubMed ID: 12885833)
1. Down syndrome and acute myeloid leukemia: the paradox of increased risk for leukemia and heightened sensitivity to chemotherapy.
Ravindranath Y
J Clin Oncol; 2003 Sep; 21(18):3385-7. PubMed ID: 12885833
[No Abstract] [Full Text] [Related]
2. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891.
Gamis AS; Woods WG; Alonzo TA; Buxton A; Lange B; Barnard DR; Gold S; Smith FO;
J Clin Oncol; 2003 Sep; 21(18):3415-22. PubMed ID: 12885836
[TBL] [Abstract][Full Text] [Related]
3. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
[TBL] [Abstract][Full Text] [Related]
4. Treatment of childhood acute myeloid leukemia.
ter Bals E; Kaspers GJ
Expert Rev Anticancer Ther; 2005 Oct; 5(5):917-29. PubMed ID: 16221060
[TBL] [Abstract][Full Text] [Related]
5. Acute leukemias in children with Down syndrome.
Zwaan MC; Reinhardt D; Hitzler J; Vyas P
Pediatr Clin North Am; 2008 Feb; 55(1):53-70, x. PubMed ID: 18242315
[TBL] [Abstract][Full Text] [Related]
6. Myeloid leukaemia in children with Down syndrome: report of the registry-based French experience between 1990 and 2003.
Tandonnet J; Clavel J; Baruchel A; Nacka F; Pérel Y
Pediatr Blood Cancer; 2010 Jul; 54(7):927-33. PubMed ID: 20405513
[TBL] [Abstract][Full Text] [Related]
7. Optimizing therapy for myeloid disorders of Down syndrome.
Webb DK
Br J Haematol; 2005 Oct; 131(1):3-7. PubMed ID: 16173956
[TBL] [Abstract][Full Text] [Related]
8. Acute myeloid leukemia and Down syndrome evolution of modern therapy--state of the art review.
Gamis AS
Pediatr Blood Cancer; 2005 Jan; 44(1):13-20. PubMed ID: 15534881
[TBL] [Abstract][Full Text] [Related]
9. Trisomy 11 limited to trisomy 21 cells in a mosaic Down syndrome child with acute myeloid leukemia.
Punnett HH; Dampier C
Med Pediatr Oncol; 2003 Jul; 41(1):69-70. PubMed ID: 12764749
[No Abstract] [Full Text] [Related]
10. Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: data from 56 children treated on NOPHO-AML protocols and a review of the literature.
Abildgaard L; Ellebaek E; Gustafsson G; Abrahamsson J; Hovi L; Jonmundsson G; Zeller B; Hasle H
Ann Hematol; 2006 May; 85(5):275-80. PubMed ID: 16518605
[TBL] [Abstract][Full Text] [Related]
11. Down syndrome, drug metabolism and chromosome 21.
Taub JW; Ge Y
Pediatr Blood Cancer; 2005 Jan; 44(1):33-9. PubMed ID: 15390307
[TBL] [Abstract][Full Text] [Related]
12. Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: the Japanese Childhood AML Cooperative Study Group.
Kudo K; Kojima S; Tabuchi K; Yabe H; Tawa A; Imaizumi M; Hanada R; Hamamoto K; Kobayashi R; Morimoto A; Nakayama H; Tsuchida M; Horibe K; Kigasawa H; Tsukimoto I;
J Clin Oncol; 2007 Dec; 25(34):5442-7. PubMed ID: 18048827
[TBL] [Abstract][Full Text] [Related]
13. Extramedullary infiltration at diagnosis and prognosis in children with acute myelogenous leukemia.
Kobayashi R; Tawa A; Hanada R; Horibe K; Tsuchida M; Tsukimoto I;
Pediatr Blood Cancer; 2007 Apr; 48(4):393-8. PubMed ID: 16550530
[TBL] [Abstract][Full Text] [Related]
14. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
Creutzig U; Zimmermann M; Lehrnbecher T; Graf N; Hermann J; Niemeyer CM; Reiter A; Ritter J; Dworzak M; Stary J; Reinhardt D
J Clin Oncol; 2006 Sep; 24(27):4499-506. PubMed ID: 16983120
[TBL] [Abstract][Full Text] [Related]
15. Acute myeloid leukaemia in patients with trisomy 21.
Collins KJ
J Paediatr Child Health; 1995 Feb; 31(1):57. PubMed ID: 7748694
[No Abstract] [Full Text] [Related]
16. [Diagnostics and therapy of acute myeloid leukemia].
Fritsch S; Metzeler K; Hiddemann W; Buske C
Dtsch Med Wochenschr; 2006 Oct; 131(43):2401-6. PubMed ID: 17054056
[No Abstract] [Full Text] [Related]
17. Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy.
Gupta V; Chun K; Yi QL; Minden M; Schuh A; Wells R; Brandwein J
Cancer; 2005 May; 103(10):2082-90. PubMed ID: 15830348
[TBL] [Abstract][Full Text] [Related]
18. [Relapsed acute myeloid leukemia with Down syndrome showing long disease-free survival after bone marrow transplantation].
Daifu T; Kato I; Matubara H; Abe D; Uryu K; Tokumasu M; Umeda K; Watanabe K; Izawa K; Asai K; Nakahata T; Adachi S
Rinsho Ketsueki; 2009 Feb; 50(2):73-7. PubMed ID: 19265297
[TBL] [Abstract][Full Text] [Related]
19. Down syndrome and acute lymphoblastic leukaemia.
Whitlock JA
Br J Haematol; 2006 Dec; 135(5):595-602. PubMed ID: 17054672
[TBL] [Abstract][Full Text] [Related]
20. Acute leukaemia in children with Down syndrome: a population-based Nordic study.
Zeller B; Gustafsson G; Forestier E; Abrahamsson J; Clausen N; Heldrup J; Hovi L; Jonmundsson G; Lie SO; Glomstein A; Hasle H;
Br J Haematol; 2005 Mar; 128(6):797-804. PubMed ID: 15755283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
